Personalized Approaches to HER2-Positive Breast Cancer Treatment (webcourse)
Credit(s): 1.00 (60 min)
Release Date: Mar 15, 2022
Expiration Date: Mar 15, 2023
Physicians – AMA PRA Category 1 Credit(s) ™
Physicians/ABIM MOC – ABIM MOC Point(s)
Nurses – Contact Hour(s)
While In recent years, the treatment of HER2-positive metastatic breast cancer has improved significantly and become increasingly individualized. Several novel therapies have emerged that provide patients progressing on first-line therapy with improved treatment options that can be personalized to their individual treatment needs. Additionally, a novel subset of breast cancer comprising patients with low HER2 expression (IHC 1 or 2) has been identified that represents up to 40% of all metastatic breast cancer. Several novel agents are in development that specifically target this low HER2 expressing population.
This activity, Personalized Approaches to HER2-Positive Breast Cancer Treatment, will provide oncology clinicians with information on the most recent treatments for HER2-positive breast cancer, expert recommendations for treatment selection and sequencing, and how to identify and treat HER2-positive patients with low HER2 expression.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
This program is supported by educational grants from AstraZeneca, Daiichi Sankyo, And Seagen.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
Diabetes and COVID-19 in the Outpatient Setting: What Clinicians Need to Know
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.